Literature DB >> 19098690

Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada.

Barbara Romanowski1, Linda N Myziuk, Sharon L Walmsley, Sylvie Trottier, Ameeta E Singh, Stanley Houston, Mark Joffe, Isabelle Chiu.   

Abstract

OBJECTIVE: To determine the seroprevalence of herpes simplex virus infection in a population of HIV-infected individuals in Canada.
METHODS: HIV-infected patients attending 5 infectious disease clinics for follow-up care were approached to participate in the study. After informed consent was obtained, subjects completed a questionnaire documenting HIV-risk behavior, duration of infection, history of oral and/or genital herpes, and treatment for HIV and/or genital herpes. Blood for HSV type-specific serology was drawn and tested by enzyme-linked immunosorbent assay (Focus Diagnostics HerpeSelect HSV-1, HSV-2 enzyme-linked immunosorbent assay IgG). Equivocal samples were repeated and any discrepant results were resolved with Western blot.
RESULTS: Six hundred twenty-nine HIV-infected individuals participated. The mean age was 43.9 years, 74.7% were Canadian born and 72.3% were men. The majority of foreign-born subjects were black (endemic) and women. The seroprevalence of HSV-1 and HSV-2 was 78.1% and 54.6%, respectively. Women were 2.7 times more likely to be HSV-2 seropositive, non-Canadian-born participants were 2.0 times more likely to be HSV-2 seropositive, and nonwhite subjects were 3.2 times more likely to be seropositive. Men who had sex with other men had the lowest seroprevalence of HSV-2. Only 30.3% of HSV-2 positive subjects reported a history of genital herpes.
CONCLUSIONS: A significant proportion of HIV-infected subjects attending 5 infectious disease clinics in Canada are coinfected with HSV. Routine type-specific HSV-2 testing should be introduced to direct education regarding symptoms, signs, and transmission reduction of genital herpes and perhaps ultimately HIV-1. Knowledge of HSV serostatus would also provide an opportunity to consider antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19098690     DOI: 10.1097/OLQ.0b013e31818d3fb6

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  11 in total

1.  Herpes simplex virus type 2 serostatus is not associated with inflammatory or metabolic markers in antiretroviral therapy-treated HIV.

Authors:  Darrell H S Tan; Janet M Raboud; Leah Szadkowski; Tae Joon Yi; Brett Shannon; Rupert Kaul; W Conrad Liles; Sharon L Walmsley
Journal:  AIDS Res Hum Retroviruses       Date:  2014-12-17       Impact factor: 2.205

2.  Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United States.

Authors:  Pragna Patel; Tim Bush; Kenneth H Mayer; Sheila Desai; Keith Henry; Edgar Turner Overton; Lois Conley; John Hammer; John T Brooks
Journal:  Sex Transm Dis       Date:  2012-02       Impact factor: 2.830

Review 3.  Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention.

Authors:  Seth C Kalichman; Jennifer Pellowski; Christina Turner
Journal:  Sex Transm Infect       Date:  2011-02-17       Impact factor: 3.519

4.  Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial.

Authors:  Darrell H S Tan; Janet M Raboud; Rupert Kaul; Beatriz Grinsztejn; Pedro Cahn; Sharon L Walmsley
Journal:  Trials       Date:  2010-11-24       Impact factor: 2.279

5.  Hospital-based HIV/HSV-2 seroprevalence among male patients with anal disease in Korea: cross sectional study.

Authors:  Jin-Sook Wang; Do Yeon Hwang; Hye-Kyung Yu; Sung Soon Kim; Jong Kyun Lee; Mee-Kyung Kee
Journal:  BMC Infect Dis       Date:  2014-01-20       Impact factor: 3.090

6.  Sexually transmitted infections in HIV-infected people in Switzerland: cross-sectional study.

Authors:  Hansjakob Furrer; Nicola Low; Katharina Sprenger; John Marc Evison; Marcel Zwahlen; Cedric M Vogt; Maria Verena Elzi; Christoph Hauser
Journal:  PeerJ       Date:  2014-08-26       Impact factor: 2.984

Review 7.  Herpes simplex virus type 2 and HIV disease progression: a systematic review of observational studies.

Authors:  Darrell Hoi-San Tan; Kellie Murphy; Prakesh Shah; Sharon Lynn Walmsley
Journal:  BMC Infect Dis       Date:  2013-10-28       Impact factor: 3.090

8.  HIV/Human herpesvirus co-infections: Impact on tryptophan-kynurenine pathway and immune reconstitution.

Authors:  Siew Hwei Yap; Noor Kamila Abdullah; Megan McStea; Kozo Takayama; Meng Li Chong; Elisa Crisci; Marie Larsson; Iskandar Azwa; Adeeba Kamarulzaman; Kok Hoong Leong; Yin Ling Woo; Reena Rajasuriar
Journal:  PLoS One       Date:  2017-10-09       Impact factor: 3.240

9.  Seroprevalence of HSV-1 and 2 in HIV-infected males with and without GUD: Study from a tertiary care setting of India.

Authors:  Arshi Munawwar; Somesh Gupta; Surendra Kumar Sharma; Sarman Singh
Journal:  J Lab Physicians       Date:  2018 Jul-Sep

10.  Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial.

Authors:  Darrell H S Tan; Janet M Raboud; Leah Szadkowski; Beatriz Grinsztejn; José Valdez Madruga; Maria Ines Figueroa; Pedro Cahn; Simon E Barton; Amanda Clarke; Julie Fox; Wendy Zubyk; Sharon L Walmsley
Journal:  J Antimicrob Chemother       Date:  2019-02-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.